Add to a list

Inactive Instrument

LOTUS PHARM Stock OTC Bulletin Board

LTUS

US5457151042

Pharmaceuticals

OTC Markets Traded

End-of-day quote OTC Bulletin Board
- ^USD	-

23-07-31	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
21-11-26	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE

Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	9.74M 8.7M 8.11M 7.35M 13.83M 924M 13.94M 97.11M 38.02M 481M 36.56M 35.76M 1.54B	P/E 2009	3.88x	P/E 2010	4.84x
Enterprise Value	14.38M 12.85M 11.98M 10.86M 20.43M 1.37B 20.59M 143M 56.16M 710M 54.01M 52.83M 2.28B	EV / Sales 2009	1.02x	EV / Sales 2010	0.95x
Free-Float	99%	Yield 2009 *	-	Yield 2010	-

23-07-31	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
21-11-26	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE
21-09-28	Lotus Pharmaceuticals : Temasek-backed Vertex expects at least $400 million in new S.E.Asia/India fund	RE
12-05-16	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS from LTUSE	CI
12-04-19	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS.E from LTUS	CI

12-30	Lotus Pharmaceutical Supports Street Medicine Program to Expand Access to Care for Those Most in Need	AQ
25-10-06	Lotus Enters License and Supply Agreement with Adalvo for Semaglutide injection	AQ
25-08-12	Lotus Pharmaceutical Achieves New First-Half Record in Revenue for 2025, While Q2 Impacted by FX and Timing of Lenalidomide Sales	AQ
25-02-21	Lotus announces FDA acceptance of Potential First-to-File ANDA Submission for Voclosporin soft gelatin capsules, a generic equivalent to Lupkynis	AQ
24-11-08	Lotus Achieves Second-Highest Quarterly Performance in Company History with 3Q24 Financial Results	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-1.36%	+0.78%	+42.36%	+91.48%	1,054B
JOHNSON & JOHNSON	-5.73%	-2.42%	+30.23%	+58.50%	636B
ABBVIE INC.	-2.40%	+2.88%	+19.13%	+85.43%	497B
MERCK & CO., INC.	-2.39%	+0.03%	+65.67%	+36.51%	359B
ROCHE HOLDING AG	-0.06%	+2.86%	+24.03%	+41.07%	345B
NOVARTIS AG	-0.55%	+1.81%	+14.16%	+36.31%	273B
ASTRAZENECA PLC	-1.08%	+1.12%	-6.93%	+6.98%	246B
AMGEN INC.	-1.13%	+2.54%	+41.19%	+45.32%	226B
GILEAD SCIENCES, INC.	-1.67%	+2.56%	+25.13%	+90.50%	187B
Average	-1.51%	+3.14%	+28.33%	+54.68%	424.69B
Weighted average by Cap.	-1.36%	+3.19%	+31.75%	+63.33%

	2009	2010
Net sales	57.82M 51.65M 48.15M 43.65M 82.15M 5.49B 82.79M 577M 226M 2.85B 217M 212M 9.16B	72.7M 64.94M 60.53M 54.88M 103M 6.9B 104M 725M 284M 3.59B 273M 267M 11.52B
Net income	16.43M 14.68M 13.68M 12.4M 23.34M 1.56B 23.53M 164M 64.16M 811M 61.71M 60.36M 2.6B	14.42M 12.89M 12.01M 10.89M 20.49M 1.37B 20.65M 144M 56.33M 712M 54.17M 52.99M 2.29B
Net Debt	5.29 4.73 4.41 4 7.52 502.51 7.58 52.8 20.67 261.34 19.88 19.45 838.62	4.65 4.15 3.87 3.51 6.6 441.08 6.65 46.35 18.14 229.39 17.45 17.07 736.1

LOTUS PHARM Stock OTC Bulletin Board

Stocks

LTUS

US5457151042

Pharmaceuticals

Valuation: LOTUS PHARM

Latest news: LOTUS PHARM

Press Releases: LOTUS PHARM

Managers and Directors: LOTUS PHARM

Generic Pharmaceuticals

Financials

Company Profile